Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial
Source: Streetwise Reports  (11/11/20)
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer. More >

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned
Source: Streetwise Reports  (11/9/20)
Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021. More >

Glaukos Shares Pressured Higher After Firm Reports 11% Rise in Q3 Revenue
Source: Streetwise Reports  (11/6/20)
Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales. More >

U.S. Biotech Developing Cancer Therapeutics Has 'Deep Pipeline'
Source: Streetwise Reports  (11/4/20)
ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report. More >

Supernus Pharma Shares Trade Up 21% on 52% Increase in Q3 YoY Revenue
Source: Streetwise Reports  (11/4/20)
Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019. More >

Multinational Phase 2b/3 COVID-19 Study Approved to Continue
Source: Streetwise Reports  (11/2/20)
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy. More >

Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End
Source: Streetwise Reports  (10/28/20)
Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial. More >

Mirati Therapeutics' Shares Rise 12.5% on Positive Data from Cancer Studies
Source: Streetwise Reports  (10/26/20)
Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies. More >

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month
Source: Streetwise Reports  (10/23/20)
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic. More >

Biotech Secures Supplier of Psilocybin, Other Psychedelics
Source: Streetwise Reports  (10/21/20)
Revive Therapeutics will use these products in future studies and clinical trials. More >

Aptinyx Shares Trade 17% Higher on Positive Top-Line Data in Phase 2 PTSD Trial
Source: Streetwise Reports  (10/20/20)
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder. More >

BioSpecifics Technologies Agrees to $658 Million Buyout Offer from Endo Pharmaceuticals
Source: Streetwise Reports  (10/19/20)
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction. More >

With Bases Loaded, NervGen Swings for the Fences in Traumatic Brain Injury
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (10/19/20)
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co. More >

Biopharma Announces Pulmonary Fibrosis Trial Now 25% Enrolled
Source: Streetwise Reports  (10/14/20)
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug. More >

Altimmune Publishes Compelling Preclinical Data for Intranasal COVID-19 Vaccine Candidate
Source: Streetwise Reports  (10/13/20)
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate. More >

StreetSmart Live! Presents Algernon Pharmaceuticals
Source: Streetwise Reports  (10/8/20)
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
More >

Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients
Source: Streetwise Reports  (10/7/20)
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report. More >

Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue
Source: Streetwise Reports  (10/7/20)
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter. More >

Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark
Source: Streetwise Reports  (10/5/20)
Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end. More >

MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb
Source: Streetwise Reports  (10/5/20)
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash. More >

AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm
Source: Streetwise Reports  (10/1/20)
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis. More >

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial
Source: Streetwise Reports  (9/30/20)
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. More >

Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (9/30/20)
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. More >

GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test
Source: Streetwise Reports  (9/28/20)
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. More >

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study
Source: Streetwise Reports  (9/23/20)
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. More >